

1 **Title: *MUC5AC* genetic variation is associated with tuberculosis meningitis CSF**
2 **cytokine responses and mortality**

3 **Authors:** Michelle C. Sabo¹, Nguyen T.T. Thuong^{2,3}, Xuling Chang⁴, Edwin Ardiansyah⁵,
4 Trinh T.B. Tram², Hoang T. Hai², Ho D.T. Nghia^{2,6}, Nguyen D. Bang^{6,7}, Sofiati Dian⁵, A.
5 Rizal Ganiem^{5,8}, Vinod Kumar⁵, Zheng Li⁹, Martin Hibberd¹⁰, Chiea Chuen Khor⁹, Guy E.
6 Thwaites^{2,3}, Dorothee Heemskerck^{2,3,11}, Arjan van Laarhoven⁵, Reinout van Crevel⁵, Sarah
7 J. Dunstan⁴, Javeed A. Shah^{1,12}

8 *¹Department of Internal Medicine, University of Washington, Seattle Washington, USA*

9 *²Oxford University Clinical Research Unit, Ho Chi Minh, Vietnam*

10 *³Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom*

11 *⁴Department of Infectious Diseases, University of Melbourne, at the Peter Doherty
12 Institute for Infection and Immunity, Melbourne, Australia*

13 *⁵Radboud University Medical Center, Nijmegen, Netherlands*

14 *⁶Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam*

15 *⁷Pham Ngoc Thach Hospital, Ho Chi Minh, Vietnam*

16 *⁸Department of Neurology, Universitas Padjadjaran/Hasan Sadikin Hospital, Bandung,
17 Indonesia*

18 *⁹Genome Institute of Singapore, Singapore*

19 *¹⁰London School of Tropical Medicine and Hygiene, London, United Kingdom*

20 *¹¹Amsterdam University Medical Centre, Amsterdam, Netherlands*

21 *¹²VA Puget Sound Healthcare System, Seattle, USA*

22

23 **Corresponding author:** Michelle C. Sabo, 325 9th Avenue, Box 359909, Seattle WA
24 98104. Phone (440) 821-7962. Fax: (206) 543-4818. Email: sabo@uw.edu

25 **Author Contributions:** MCS, NTTT and JAS conceptualized and designed this analysis.
26 MCS, NTTT, XC, SD, EA, AL, RC, VK, CCK, ZL, and JAS participated in analysis and
27 interpretation of data. Acquisition of data was performed by ARG, HDTN, NDB, GET,
28 DH, TTBT, HTH, CK, MH and SD. MCS and JAS drafted the original manuscript, with
29 XC and SD contributing important intellectual content during the drafting process. All
30 authors have approved the final version of this article prior to submission and agree to be
31 accountable for all aspects of the manuscript, including questions related to accuracy and
32 integrity of the work.

33 **Funding:** This work was supported by the National Institute of Child Health and Human
34 Development [1K23HD100221 to MCS] and the National Institute of Allergy and Infectious
35 Diseases [R01 AI136921 to JAS and R01AI145781 to AvL, VK and RvC], both at the
36 National Institutes of Health, the University of Washington Center for AIDS Research
37 [AI027757 to MCS], the Wellcome Trust Intermediate Fellowship in Public Health and
38 Tropical Medicine [206724/Z/17/Z to NTTT], Wellcome Trust Major Overseas Program
39 Funding [106680/B/14/Z to GT], and the National Health and Medical Research Council,
40 Australia (APP1056689 to SJD).

41 **Running title:** Tuberculosis meningitis and *MUC5AC*

42 **Impact of Research:** Mortality from tuberculosis meningitis remains unacceptably high.
43 This is the first study to show an association between risk of death from tuberculosis
44 meningitis and a polymorphism in *MUC5AC*, which is an important gel-forming mucin
45 expressed in lungs.

46 **Subject category:** 11.4 Mycobacterial Disease: Host Defenses

47 **Total word count:** 2,938

48

49

50 **ABSTRACT**

51 **Rationale:** Lung mucins are an understudied component of the mucosal immune
52 response and may influence tuberculosis pathogenesis and outcomes.

53 **Objectives:** To assess if variants in lung mucins *MUC5B* and *MUC5AC* are associated
54 with *Mycobacterium tuberculosis* immune responses, susceptibility, and outcomes.

55 **Methods:** We characterized four haplotype tagging single nucleotide polymorphisms
56 (SNPs) in *MUC5B* and *MUC5AC* for association with \log_2 TNF concentrations in cerebral
57 spinal fluid (CSF) from TBM patients. SNPs associated with CSF TNF concentrations
58 were carried forward for analyses of pulmonary and meningeal TB susceptibility and TBM
59 mortality.

60 **Measurements and Main Results:** *MUC5AC* SNP rs28737416 T allele was associated
61 with lower CSF concentrations of TNF($p=1.8 \times 10^{-8}$) and $\text{IFN}\gamma$ ($p=2.3 \times 10^{-6}$), and higher TBM,
62 but not pulmonary TB, susceptibility (OR 1.24, 95% confidence interval 1.03, 1.49;
63 $p=0.021$). Mortality from TBM was higher among participants with the rs28737416 T/T
64 and T/C genotype (35/119, 30.4%) versus the C/C genotype (11/89, 12.4%; log-rank
65 $p=0.005$) in a Vietnamese cohort (N=211). This finding was confirmed in an independent
66 Vietnamese validation cohort (N=87; 9/87, 19.1% vs 1/20, 2.5%; log-rank $p=0.02$) and an
67 Indonesian validation cohort (N=468, 127/287, 44.3% vs 65/181, 35.9%, log-rank
68 $p=0.06$).

69 **Conclusions:** The *MUC5AC* rs28737416 T/T and T/C genotypes were associated with
70 higher susceptibility and mortality from TBM and lower CSF concentrations of TNF and
71 $\text{IFN}\gamma$ compared to the C/C genotype, suggesting that *MUC5AC* contributes to immune
72 changes that influence TBM outcomes.

73 **Abstract word count:** 224

74 **Keywords:** Tuberculosis meningitis, MUC5AC, genetics, mucin

75 INTRODUCTION

76 Tuberculosis (TB) leads to over one million deaths annually (1). The clinical
77 phenotype of TB disease is highly heterogenous, ranging from asymptomatic to severe
78 disseminated infection and death (2). Tuberculosis meningitis (TBM) is the deadliest form
79 of TB and leads to death or neurologic sequelae in over half of affected individuals (3).
80 However, the factors that predispose individuals to symptomatic TB and TBM
81 susceptibility and mortality are incompletely understood.

82 Lung mucins are complex glycoproteins on the surface of airway epithelia that
83 inactivate potential pathogens and modulate immune signaling (4, 5). The two gel-
84 forming mucins in the lungs, *MUC5B* and *MUC5AC*, are encoded by adjacent genes on
85 chromosome 11p15.5 and are essential for lung health (4, 6, 7). Mice and humans with
86 genetic mutations lacking *MUC5B* develop severe pneumonia and upper airway
87 obstruction due to impaired mucociliary clearance, whereas overexpression leads to
88 pulmonary fibrosis (8-11). Similarly, *MUC5AC* is strongly induced by inflammation and
89 influences pathogen clearance, asthma pathogenesis, and may contribute to TB immune
90 escape during helminthic co-infection by altering inflammatory responses (12-16).
91 Therefore, mucins may influence initial TB infection by altering mucociliary clearance and
92 initial infection of alveolar macrophages or TB dissemination by altering dynamics of
93 inflammation. However, the role of mucins in TB pathogenesis is unknown.

94 Multiple lines of evidence demonstrate that host genetics influence TB risk (17).
95 Prior genetic association studies have generally focused on immune recognition and
96 response mediators. Variation in Toll-like receptor (TLR) 2, TLR9, mannose binding
97 protein (MBP), leukotriene A4 hydrolase (LTA4H), and toll interacting protein (TOLLIP),

98 have been associated with TBM susceptibility (18-22). Similarly, LTA4H and CD43
99 variants have been linked to higher risk of mortality from TBM (23, 24). However, the
100 influence of genetic polymorphisms in non-immune factors produced in the lung, such as
101 mucins, on immune function, TB susceptibility, or extrapulmonary spread are not known.

102 Genetic studies provide a powerful tool for examining how novel genes, such as
103 mucin genes, influence TB pathogenesis. Evaluation of immune phenotypes that
104 correlate with disease outcomes may detect novel variants associated with TB
105 susceptibility and mortality. Studies of genetically regulated cytokine responses in
106 *Bacillus Calmette-Guerin* (BCG)-specific T cells, dendritic cells, and peripheral blood
107 mononuclear cells (PBMCs) have identified potential TB susceptibility factors (21, 25-27).
108 Variants that influence functional responses in tissues of interest represent attractive
109 secondary traits that can be correlated with TB susceptibility, and these correlations may
110 provide insight into genetic mechanisms of disease susceptibility (25)(28). Because CSF
111 TNF concentrations have been linked with TBM outcomes and pathogenesis (23, 29), we
112 evaluated variants in the mucin gene region for association with TNF and other CSF
113 cytokines, followed by evaluation of candidate susceptibility SNPs with tuberculosis
114 outcomes, including pulmonary TB and TBM susceptibility, morbidity, and mortality.

115

116

117 **METHODS**

118 ***SNP selection***

119 Genotyping and single nucleotide polymorphism (SNP) quality control (QC) are
120 described in the **Supplementary Methods**. SNPs within and around (\pm 10kb), the

121 *MUC5B* and *MUC5AC* gene region were identified using a haplotype-tagging approach
122 from a genome-wide SNP dataset of TBM cases (N=407) and primary angle closure
123 glaucoma (PACG) controls (N=1,139) (21, 30). Four SNPs were selected based on
124 linkage disequilibrium (LD, $r^2 < 0.1$).

125 As a screening step, the four selected SNPs were evaluated for associations with
126 \log_2 concentrations (pg/mL) of TNF in cerebral spinal fluid (CSF) collected at enrollment
127 from 154 participants in the discovery cohort (defined below). Cytokine concentrations
128 and CSF leukocytes were measured and compared using standard statistical methods
129 (see **Supplementary Methods**) (31). Only SNPs associated with significant changes in
130 \log_2 TNF CSF concentrations were carried forward in further analyses. The association
131 between SNPs of interest and CSF cytokine concentrations was confirmed using data
132 from validation cohort 2 (N=468, defined below) as described in the **Supplementary**
133 **Methods**.

134

135 ***Evaluation of TB Outcomes***

136 The association between SNPs of interest and TBM status was assessed between
137 TBM cases (N=407) and PACG controls (N=1,1339) (21, 30) using logistic regression
138 based on an additive genetic model (AA versus [vs] Aa vs aa), with adjustment for the
139 first three principal components (PCs) using plink v1.9 (32). Analyses were repeated
140 using cases of pulmonary TB as described in the **Supplementary Methods**.

141 The association between *MUC5AC* SNP rs28737416 and TBM morbidity and
142 mortality was analyzed in a discovery cohort consisting of participants enrolled in a study
143 of intensified therapy (including dexamethasone) in Vietnam (ISRCTN61649292) for

144 whom genotyping data were available (N=211, all HIV-1 seronegative) (33). The
145 association between rs28737416 and time to death due to TBM (33) were evaluated using
146 Kaplan-Meier estimates and compared by log-rank testing (survival package version 3.2-
147 13, R version 4.0.2). Hazard ratios were calculated using the Cox proportional hazards
148 model. Potential confounders, including i) weight; ii) duration of illness; iii) age; and iv)
149 Glasgow coma score (GCS) were evaluated for associations with the outcomes of
150 interest; those with a p-value ≤ 0.2 were used in adjusted analyses.

151 Survival analyses were repeated in two independent cohorts. The Vietnam
152 validation cohort included 87 participants enrolled in a randomized trial in Vietnam to
153 assess TBM survival with dexamethasone therapy (34). All participants with genotyping
154 data available were HIV-1 seronegative. For consistency with the Vietnam discovery
155 cohort, only participants who received dexamethasone were included. The Indonesia
156 validation cohort included 418 HIV-1 seronegative and 50 HIV-1 seropositive participants
157 enrolled in a prospective cohort study of TBM in Indonesia, all of whom received
158 dexamethasone (35, 36).

159 Information on censoring and missing data are in the **Supplementary Methods**.
160 All participants provided written, informed consent. Country and institution specific ethical
161 approvals were obtained as described (21, 30, 33-35).

162

163 ***Evaluation of expression quantitative trait loci (eQTLs)***

164 The association between SNPs and mucin mRNA expression in lung tissue was
165 evaluated using the Genotype-Tissue Expression Project (GTEx) eQTL Calculator

166 (<https://www.gtexportal.org/home/testyourown>, accessed 07/27/2021; see
167 **Supplementary Methods**) (37).

168

169

170 **RESULTS**

171 ***A MUC5AC promoter region SNP is associated with lower concentrations of CSF***

172 ***TNF and IFN γ***

173 A total of 126 SNPs were available in the TBM genome-wide SNP dataset within
174 and around (\pm 10kb) the *MUC5B* and *MUC5AC* gene region. Three tagging SNPs were
175 identified in *MUC5B*, and one tagging SNP was identified in the *MUC5AC* promoter region
176 (**Figure 1A**). None of the *MUC5B* or *MUC5AC* SNPs were in high LD with one another
177 (**Figure 1B**). *MUC5AC* SNP rs28737416 was not in LD with either of two *TOLLIP* gene
178 SNPs (rs5743854 and rs3750920) previously linked to TBM susceptibility (**Table E1**) (21,
179 26).

180 Next, we analyzed the association between haplotype tagging SNPs and TNF
181 expression in CSF collected from participants enrolled in the Vietnam discovery cohort.
182 Using an allelic genetic model as our primary screening analysis, the major (C) allele in
183 *MUC5AC* SNP rs28737416 was associated with a median 2.7-fold log₂ higher
184 concentration of CSF TNF compared to the minor (T) allele ($p=7.2 \times 10^{-8}$; **Figure 2A**). No
185 other SNPs were associated with changes in CNS TNF cytokine concentrations. We
186 compared alternate genetic models (additive, AA versus [vs.] Aa vs. aa genotypes and
187 dominant, AA vs. Aa/aa genotypes) of inheritance to determine the best fitting model
188 (**Figure 2B and 2C**). The dominant model best fit this data, so we used this model for all

189 future genetic analyses. Using this approach, SNP rs28737416 T/T and T/C genotypes
190 were significantly associated with lower CSF concentrations of TNF ($p=1.8 \times 10^{-8}$) and IFN γ
191 ($p=2.3 \times 10^{-6}$), and higher CSF concentrations of IL-2 ($p=4.8 \times 10^{-6}$) and IL-10 ($p=0.0047$)
192 after application of a Bonferroni corrected (0.05/10 cytokines) p-value threshold of <0.005
193 (**Figure 2C**).

194 We performed PCA of cytokine concentrations to evaluate the relationship
195 between cytokines and reduce the number of statistical comparisons. We found two
196 uncorrelated factors, Factor 1 and Factor 2 ($R^2=0.08$). Factor 1 had an eigenvalue of 5.46,
197 explaining 74.1% of the variability in the data. Factor 2 had an eigenvalue of 1.02,
198 explaining 13.8% variability in the data, and was influenced almost entirely by variability
199 in TNF (loading value=0.59) and IFN γ (loading value=0.57) (see **Supplementary**
200 **Results**). Factor 1 was not associated with the presence of the C/C genotype
201 (exponentiated [exp] $\beta=0.88$, 95% CI 0.73, 1.06; $p=0.19$). However, Factor 2 was
202 associated with the C/C genotype (exp $\beta=0.63$, 95% CI 0.50, 0.79; $p=4.9 \times 10^{-5}$), suggesting
203 that variations in TNF and IFN γ concentrations are influenced by differences in genotype.

204 We validated the association of rs28737416 with TNF concentrations in the CSF
205 collected from participants in the Indonesia validation cohort. As in the Vietnam discovery
206 cohort, the T/T and T/C genotype of rs28737416 was associated with lower TNF
207 concentrations (estimate [est] = -0.44, $p=0.008$) and IFN γ (est = -0.67, $p=0.03$). The
208 relationship between expression of additional CSF cytokines and TBM in this cohort are
209 presented in Table **E2**. These data demonstrate the generalizability of this genetic
210 phenotype of TBM immune response across ethnically distinct populations.

211 Based on these preliminary observations, we evaluated the association between
212 the candidate SNP rs28737416 and total number of CSF white blood cells ($\text{exp}\beta=1.23$,
213 95% CI 0.90, 1.70; $p=0.19$), neutrophils ($\text{exp}\beta=1.05$, 95% CI 0.83, 1.34; $p=0.68$), and
214 lymphocytes ($\text{exp}\beta=1.25$, 95% CI 0.90,1.74; $p=0.18$) in the Vietnam discovery cohort
215 using a dominant genotypic model. The $\text{exp}\beta$ representing the mean change in cell
216 concentration between participants with a composite of the T/C and T/T genotypes
217 compared to participants with the C/C genotype. These data suggest that *MUC5AC* SNP
218 rs28737416 T allele is associated with lower CSF concentrations of TNF and $\text{IFN}\gamma$ in
219 individuals with TBM, independent from total CSF cell count.

220

221 ***MUC5AC* SNP rs28737416 is associated with TBM susceptibility and mortality**

222 Because rs28737416 T allele was associated with lower TNF in individuals with
223 TBM, we further analyzed the association between *MUC5AC* SNP rs28737416 and TBM
224 susceptibility by case-control analysis (see methods). SNP rs28737416 was associated
225 with susceptibility to TBM (OR=1.24, 95% CI 1.03, 1.49; $p=0.02$) (**Table 1**), but not
226 pulmonary TB (OR=1.11, 95% CI 0.98, 1.25; $p=0.10$).

227 Selected genes may influence progression of disease above susceptibility (24), so
228 we next considered whether *MUC5AC* SNP rs28737416 was associated with TBM
229 mortality in the Vietnam discovery cohort and two independent validation cohorts.
230 Baseline characteristics for each cohort are shown in **Table 2**.

231 Survival analyses were first performed in the Vietnam discovery cohort with SNP
232 rs28737416. We found a greater proportion of participants with T/T and T/C genotypes
233 died (35/119, 30.4%) compared to those with the C/C genotype (11/89, 12.4%) ($p=0.005$)

234 **(Figure 3A)**, which corresponded to a 61% lower risk of death among participants with
235 the C/C genotype (hazard ratio [HR] 0.39, 95% CI 0.20, 0.77; $p=0.006$). This association
236 persisted after adjustment for age and GCS (adjusted HR [aHR] 0.31, 95% CI 0.16, 0.63;
237 $p=0.001$). Adjustment for principal components representing genetic substructure did not
238 alter the results (data not shown). SNP rs2873716 T allele was associated with higher
239 risk mortality in an additive model as well **(Figure E1)**.

240 Results were confirmed in a Vietnam validation cohort and a separate Indonesia
241 validation cohort. In the Vietnam validation cohort, more T/T and T/C participants (9/47,
242 19.1%) died compared to those with the C/C genotype (1/40, 2.5%; $p=0.02$) **(Figure 4A)**,
243 representing an 87.1% lower risk of death from TBM (HR 0.13, 95% CI 0.02, 1.02,
244 $p=0.05$). The association was similar after adjustment for age, weight, and GCS (aHR
245 0.13, 95% CI 0.02, 1.13; $p=0.06$).

246 We measured the association between rs28737416 and TBM mortality in the
247 Indonesia validation cohort, which included both HIV-1 seronegative (N=418) and
248 seropositive (N=50) participants. A higher number of participants with the rs28737416 T/T
249 and T/C genotypes died (127/287, 44.3%) compared to those with the C/C genotype
250 (65/181, 35.9%, $p=0.06$) **(Figure 4B)**, corresponding to a 20.1% lower risk of death
251 among participants with the C/C genotype (HR 0.80, 95% CI 0.66, 0.99; $p=0.04$).
252 However, this association was attenuated after adjustment for age and GCS (aHR=0.87,
253 95% CI 0.69, 1.09 $p=0.22$). In sensitivity analyses using only HIV seronegative
254 participants, more participants with the T/T and T/C genotypes (106/252, 42.1%) died
255 compared to those with the C/C genotype (56/166, 33.7%, $p=0.08$). The resultant risk of
256 death was 24.8% lower among participants with the C/C genotype, and of borderline

257 statistical significance (HR=0.75, 95% CI 0.54, 1.04; p=0.08) (**Figure E2**). Data on the
258 proportional hazards assumptions for both the discovery and validation cohorts is
259 included in the **Supplementary Results**. Taken together, these data suggest that
260 *MUC5AC* SNP rs28737416 is associated with TBM susceptibility and mortality.

261 ***SNP rs28737416 is associated with mRNA expression of MUC5AC but not MUC5B***

262 To explore potential mechanisms for the association between mucins and TBM
263 mortality, the association between rs28737416 and *MUC5B* / *MUCAC* mRNA expression
264 in healthy lung tissues was assessed using public datasets (37). Participants with the T/T
265 (0.11) genotype had significantly higher median normalized *MUC5AC* mRNA expression
266 compared to those with the T/C (0.06) or C/C (-0.05) genotype (normalized effect size
267 [NES] -0.14, p=0.009). There was no association between rs28737416 and *MUC5B*
268 expression in lung tissues (NES= -0.021, p=0.67). Thus, the rs28737416 T allele is
269 associated with higher basal *MUC5AC* expression in lung tissue, lower CSF expression
270 of TNF and IFN γ , and higher risk of TBM mortality.

271

272 **DISCUSSION**

273 This is the first study to link polymorphisms in a mucin gene with tuberculosis
274 disease. Specifically, SNP rs28737416 T allele was associated with higher expression
275 of *MUC5AC* in lung tissues, lower CSF concentrations of TNF and IFN γ in participants
276 with TBM, and higher susceptibility and risk of death from TBM. These findings suggest
277 that the mucosal barrier plays an important role in *Mycobacterium tuberculosis*
278 pathogenesis.

279 Common variants in *MUC5AC* are associated with lung diseases, including
280 COVID-19, and asthma (38-40). Each of these variants are in strong LD with our variant
281 of interest in the Vietnamese population, suggesting that functional variation in *MUC5AC*
282 may influence disease outcomes. In this study, genetic variation associated with
283 diminished *MUC5AC* expression in the lungs of healthy individuals was protective from
284 development of TBM. *MUC5AC* is induced during inflammation and protects against viral
285 infection (4, 14, 15). However, over-expression of *MUC5AC* is associated with severe
286 asthma exacerbation and ventilator-associated lung injury (13, 41). Thus, our findings fit
287 a model where *MUC5AC* contributes to the pathogenesis of respiratory inflammation and
288 infection.

289 How *MUC5AC* contributes to TBM mortality is unclear. It is unlikely that *MUC5AC*
290 directly influences meningeal inflammation, as *MUC5AC* is not expressed in the central
291 nervous system or within *M. tuberculosis*-infected myeloid cells (42). One possible
292 explanation for the findings presented here is that over-expression of *MUC5AC* facilitates
293 breakdown of the mucosal barrier, alveolar passage through the respiratory epithelium,
294 and dissemination of *M. tuberculosis*. A similar mechanism of action has been proposed
295 for the complement protein mannose binding protein (MBP), which may promote
296 dissemination to the brain at higher concentrations (22, 43). Furthermore, *MUC5AC* may
297 influence systemic immune responses, leading to altered *M. tuberculosis* pathogenesis.
298 For example, *MUC5AC* variants are associated with total peripheral eosinophil count,
299 suggesting that *MUC5AC* may play a role in conditioning systemic immune responses
300 (38, 44). In this study, TNF and IFN γ concentrations were lower in the CSF of participants
301 with the susceptible phenotype, while IL-2 concentrations were higher. These findings are

302 consistent with other studies demonstrating that lower concentrations of CSF TNF and
303 IFN γ are associated with TBM mortality among persons who receive dexamethasone
304 therapy (23).

305 Based on the pattern of cytokines influenced rs28737416, *MUC5AC* may be
306 important for the development of effective T cell responses during *M. tuberculosis*
307 infection. Protective T cell responses against *M. tuberculosis* are generated when *M.*
308 *tuberculosis* antigens are trafficked by dendritic cells from the lung to draining lymph
309 nodes (LN), leading to T cell activation and differentiation (45, 46). Polymorphisms in
310 *MUC5AC* may delay DC migration to the LN, which impairs immunity to *M. tuberculosis*
311 in mice (46). Further study using methods to measure macrophage and T cell responses
312 in the presence of *MUC5AC* polymorphisms will be required to better understand how
313 *MUC5AC* influences TBM pathogenesis.

314 This study should be interpreted in the context of several limitations. First, it is
315 possible that the susceptibility findings from the case-control analysis were detected due
316 to another SNP (eQTL) being responsible for the change in *MUC5AC* expression.
317 However, this appears unlikely, as rs28737416 was only associated with *MUC5AC*.
318 Second, there is a potential for confounding due to population structure in the highly
319 homogenous Vietnamese population. To address this potential limitation, adjustment for
320 principal components representative of genetic substructure was performed and did not
321 significantly alter the results. Additionally, the findings were confirmed in a separate
322 cohort of participants in Indonesia, further suggesting genetic substructure was not
323 influencing these results. The association in the Indonesia validation cohort was not as
324 strong as in the Vietnamese cohorts, although the similarity in the trend in an ethnically

325 distinct cohort provides additional evidence for an association between *MUC5AC* and
326 TBM. The reason for this discrepancy may be due to differences in i) illness severity or
327 time to clinical presentation across cohorts; ii) sample-sizes between cohorts; iii), linkage
328 disequilibrium patterns across ethnicity; or, iv) environmental influence. Nonetheless,
329 these data provide some of the strongest genetic association between a polymorphism
330 and TBM currently. Future studies in additional cohorts and ongoing fine mapping studies
331 may provide further insights into this modest discrepancy (23, 47, 48). Third, some
332 participants may have been misclassified at enrollment with TBM. However, classification
333 of TBM was performed using pre-specified criteria, which generally results in random
334 misclassification (e.g., non-differential misclassification) and would bias away from finding
335 an association. Fourth, although we found an association between rs28737416 and lung
336 expression, *MUC5AC* is also expressed in the gastrointestinal tract. It is possible that
337 TBM susceptibility is modified by changes in gut microbiota that are influenced by
338 *MUC5AC* (47). Thus, these findings provide intriguing data for future mechanistic study.

339 In summary, polymorphisms in *MUC5AC* are associated with higher lung *MUC5AC*
340 mRNA expression, lower TNF and IFN γ in the CSF, and higher risk of mortality due to
341 TBM. These data provide evidence that respiratory mucins play an important role in TBM
342 pathogenesis.

343

344 **ACKNOWLEDGEMENTS**

345 We would like to thank all the participants in the parent studies used in these
346 analyses. We would also like to acknowledge the clinical, laboratory and administrative
347 staff at each study site for their dedication and assistance with this project. Finally, we
348 would like to acknowledge the GTEx Project, which supports the platform on which eQTL
349 analyses were performed. At the time of publication, the GTEx Project was supported by
350 the [Common Fund](#) of the Office of the Director of the National Institutes of Health, and by
351 NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. The data used for the analyses described
352 in this manuscript were obtained from the GTEx Portal eQTL calculator on 07/28/2021.

353

354

355 REFERENCES

- 356 1. Furin J, Cox H, Pai M. Tuberculosis. *Lancet* 2019; 393: 1642-1656.
- 357 2. Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme CC, Ginsberg A, Swaminathan
358 S, Spigelman M, Getahun H, Menzies D, Raviglione M. Tuberculosis. *Nat Rev Dis*
359 *Primers* 2016; 2: 16076.
- 360 3. Stadelman AM, Ellis J, Samuels THA, Mutengesa E, Dobbin J, Ssebambulidde K,
361 Rutakingirwa MK, Tugume L, Boulware DR, Grint D, Cresswell FV. Treatment Outcomes
362 in Adult Tuberculous Meningitis: A Systematic Review and Meta-analysis. *Open Forum*
363 *Infect Dis* 2020; 7: ofaa257.
- 364 4. Lillehoj EP, Kato K, Lu W, Kim KC. Cellular and molecular biology of airway mucins. *Int Rev*
365 *Cell Mol Biol* 2013; 303: 139-202.
- 366 5. McShane A, Bath J, Jaramillo AM, Ridley C, Walsh AA, Evans CM, Thornton DJ, Ribbeck K.
367 Mucus. *Curr Biol* 2021; 31: R938-R945.
- 368 6. Nucleotide [Internet]. Bethesda (MD): National Library of Medicine (US) NCfBIANN, Homo
369 sapiens mucin 5AC, oligomeric mucus/gel-forming (MUC5AC), mRNA; [cited
370 2021/09/20]. Available from: https://www.ncbi.nlm.nih.gov/nucore/NM_001304359.2.
- 371 7. Nucleotide [Internet]. Bethesda (MD): National Library of Medicine (US) NCfBIANN, Homo
372 sapiens mucin 5B, oligomeric mucus/gel-forming (MUC5B), mRNA; [cited 2021/09/20].
373 Available from: https://www.ncbi.nlm.nih.gov/nucore/NM_002458.3.
- 374 8. Seibold MA, Wise AL, Speer MC, Steele MP, Brown KK, Loyd JE, Fingerlin TE, Zhang W,
375 Gudmundsson G, Groshong SD, Evans CM, Garantziotis S, Adler KB, Dickey BF, du
376 Bois RM, Yang IV, Herron A, Kervitsky D, Talbert JL, Markin C, Park J, Crews AL, Slifer
377 SH, Auerbach S, Roy MG, Lin J, Hennessy CE, Schwarz MI, Schwartz DA. A common
378 MUC5B promoter polymorphism and pulmonary fibrosis. *N Engl J Med* 2011; 364: 1503-
379 1512.

- 380 9. Hancock LA, Hennessy CE, Solomon GM, Dobrinskikh E, Estrella A, Hara N, Hill DB, Kissner
381 WJ, Markovetz MR, Grove Villalon DE, Voss ME, Tearney GJ, Carroll KS, Shi Y,
382 Schwarz MI, Thelin WR, Rowe SM, Yang IV, Evans CM, Schwartz DA. Muc5b
383 overexpression causes mucociliary dysfunction and enhances lung fibrosis in mice. *Nat*
384 *Commun* 2018; 9: 5363.
- 385 10. Roy MG, Livraghi-Butrico A, Fletcher AA, McElwee MM, Evans SE, Boerner RM, Alexander
386 SN, Bellinghausen LK, Song AS, Petrova YM, Tuvim MJ, Adachi R, Romo I, Bordt AS,
387 Bowden MG, Sisson JH, Woodruff PG, Thornton DJ, Rousseau K, De la Garza MM,
388 Moghaddam SJ, Karmouty-Quintana H, Blackburn MR, Drouin SM, Davis CW, Terrell
389 KA, Grubb BR, O'Neal WK, Flores SC, Cota-Gomez A, Lozupone CA, Donnelly JM,
390 Watson AM, Hennessy CE, Keith RC, Yang IV, Barthel L, Henson PM, Janssen WJ,
391 Schwartz DA, Boucher RC, Dickey BF, Evans CM. Muc5b is required for airway
392 defence. *Nature* 2014; 505: 412-416.
- 393 11. Costain G, Liu Z, Mennella V, Radicioni G, Goczi AN, Albulescu A, Walker S, Ngan B,
394 Manson D, Vali R, Khan M, Palaniyar N, Hill DB, Hall DA, Marshall CR, Knowles M,
395 Zariwala MA, Kesimer M, Dell SD. Hereditary Mucin Deficiency Caused by Biallelic Loss
396 of Function of MUC5B. *Am J Respir Crit Care Med* 2022; 205: 761-768.
- 397 12. Monin L, Griffiths KL, Lam WY, Gopal R, Kang DD, Ahmed M, Rajamanickam A, Cruz-
398 Lagunas A, Zuniga J, Babu S, Kolls JK, Mitreva M, Rosa BA, Ramos-Payan R, Morrison
399 TE, Murray PJ, Rangel-Moreno J, Pearce EJ, Khader SA. Helminth-induced arginase-1
400 exacerbates lung inflammation and disease severity in tuberculosis. *J Clin Invest* 2015;
401 125: 4699-4713.
- 402 13. Altman MC, Flynn K, Rosasco MG, Dapas M, Kattan M, Lovinsky-Desir S, O'Connor GT, Gill
403 MA, Gruchalla RS, Liu AH, Pongracic JA, Khurana Hershey GK, Zoratti EM, Teach SJ,
404 Rastroggi D, Wood RA, Bacharier LB, LeBeau P, Gergen PJ, Togias A, Busse WW,
405 Presnell S, Gern JE, Ober C, Jackson DJ, Consortium NICA. Inducible expression

- 406 quantitative trait locus analysis of the MUC5AC gene in asthma in urban populations of
407 children. *J Allergy Clin Immunol* 2021.
- 408 14. Cho HY, Park S, Miller L, Lee HC, Langenbach R, Kleeberger SR. Role for Mucin-5AC in
409 Upper and Lower Airway Pathogenesis in Mice. *Toxicol Pathol* 2021; 49: 1077-1099.
- 410 15. Ehre C, Worthington EN, Liesman RM, Grubb BR, Barbier D, O'Neal WK, Sallenave JM,
411 Pickles RJ, Boucher RC. Overexpressing mouse model demonstrates the protective role
412 of Muc5ac in the lungs. *Proc Natl Acad Sci U S A* 2012; 109: 16528-16533.
- 413 16. Hasnain SZ, Evans CM, Roy M, Gallagher AL, Kindrachuk KN, Barron L, Dickey BF, Wilson
414 MS, Wynn TA, Grencis RK, Thornton DJ. Muc5ac: a critical component mediating the
415 rejection of enteric nematodes. *J Exp Med* 2011; 208: 893-900.
- 416 17. Correa-Macedo W, Cambri G, Schurr E. The Interplay of Human and Mycobacterium
417 Tuberculosis Genomic Variability. *Front Genet* 2019; 10: 865.
- 418 18. Thuong NT, Hawn TR, Thwaites GE, Chau TT, Lan NT, Quy HT, Hieu NT, Aderem A, Hien
419 TT, Farrar JJ, Dunstan SJ. A polymorphism in human TLR2 is associated with increased
420 susceptibility to tuberculous meningitis. *Genes Immun* 2007; 8: 422-428.
- 421 19. Tobin DM, Vary JC, Jr., Ray JP, Walsh GS, Dunstan SJ, Bang ND, Hagge DA, Khadge S,
422 King MC, Hawn TR, Moens CB, Ramakrishnan L. The Ita4h locus modulates
423 susceptibility to mycobacterial infection in zebrafish and humans. *Cell* 2010; 140: 717-
424 730.
- 425 20. Graustein AD, Horne DJ, Arentz M, Bang ND, Chau TT, Thwaites GE, Caws M, Thuong NT,
426 Dunstan SJ, Hawn TR. TLR9 gene region polymorphisms and susceptibility to
427 tuberculosis in Vietnam. *Tuberculosis (Edinb)* 2015; 95: 190-196.
- 428 21. Shah JA, Vary JC, Chau TT, Bang ND, Yen NT, Farrar JJ, Dunstan SJ, Hawn TR. Human
429 TOLLIP Regulates TLR2 and TLR4 Signaling and Its Polymorphisms Are Associated
430 with Susceptibility to Tuberculosis. *J Immunol* 2012; 189: 1737-1746.

- 431 22. Hoal-Van Helden EG, Epstein J, Victor TC, Hon D, Lewis LA, Beyers N, Zurakowski D,
432 Ezekowitz AB, Van Helden PD. Mannose-binding protein B allele confers protection
433 against tuberculous meningitis. *Pediatr Res* 1999; 45: 459-464.
- 434 23. Thuong NTT, Heemskerk D, Tram TTB, Thao LTP, Ramakrishnan L, Ha VTN, Bang ND,
435 Chau TTH, Lan NH, Caws M, Dunstan SJ, Chau NVV, Wolbers M, Mai NTH, Thwaites
436 GE. Leukotriene A4 Hydrolase Genotype and HIV Infection Influence Intracerebral
437 Inflammation and Survival From Tuberculous Meningitis. *J Infect Dis* 2017; 215: 1020-
438 1028.
- 439 24. Campo M, Randhawa AK, Dunstan S, Farrar J, Caws M, Bang ND, Lan NN, Hong Chau TT,
440 Horne DJ, Thuong NT, Thwaites GE, Hawn TR. Common polymorphisms in the CD43
441 gene region are associated with tuberculosis disease and mortality. *Am J Respir Cell
442 Mol Biol* 2015; 52: 342-348.
- 443 25. Venkatasubramanian S, Pryor R, Plumlee C, Cohen SB, Simmons JD, Warr AJ, Graustein
444 AD, Saha A, Hawn TR, Urdahl KB, Shah JA. TOLLIP Optimizes Dendritic Cell
445 Maturation to Lipopolysaccharide and Mycobacterium tuberculosis. *J Immunol Baltim Md
446 1950* 2022.
- 447 26. Shah JA, Musvosvi M, Shey M, Horne DJ, Wells RD, Peterson GJ, Cox JS, Daya M, Hoal
448 EG, Lin L, Gottardo R, Hanekom WA, Scriba TJ, Hatherill M, Hawn TR. A Functional
449 Toll-Interacting Protein Variant Is Associated with Bacillus Calmette-Guerin-Specific
450 Immune Responses and Tuberculosis. *Am J Respir Crit Care Med* 2017; 196: 502-511.
- 451 27. Li Y, Oosting M, Deelen P, Ricano-Ponce I, Smeekens S, Jaeger M, Matzaraki V, Swertz
452 MA, Xavier RJ, Franke L, Wijmenga C, Joosten LA, Kumar V, Netea MG. Inter-individual
453 variability and genetic influences on cytokine responses to bacteria and fungi. *Nat Med*
454 2016; 22: 952-960.
- 455 28. Shah JA, Warr AJ, Graustein AD, Saha A, Dunstan SJ, Thuong NTT, Thwaites GE, Caws
456 M, Thai PVK, Bang ND, Chau TTH, Khor CC, Li Z, Hibberd M, Chang X, Nguyen FK,

- 457 Hernandez CA, Jones MA, Sassetti CM, Fitzgerald KA, Musvosvi M, Gela A, Hanekom
458 WA, Hatherill M, Scriba TJ, Hawn TR. REL and BHLHE40 Variants Are Associated with
459 IL-12 and IL-10 Responses and Tuberculosis Risk. *The Journal of Immunology* 2022:
460 ji2100671.
- 461 29. Whitworth LJ, Troll R, Pagan AJ, Roca FJ, Edelstein PH, Troll M, Tobin DM, Phu NH, Bang
462 ND, Thwaites GE, Thuong NTT, Sewell RF, Ramakrishnan L. Elevated cerebrospinal
463 fluid cytokine levels in tuberculous meningitis predict survival in response to
464 dexamethasone. *Proc Natl Acad Sci U S A* 2021; 118.
- 465 30. Khor CC, Do T, Jia H, Nakano M, George R, Abu-Amero K, Duvesh R, Chen LJ, Li Z,
466 Nongpiur ME, Perera SA, Qiao C, Wong HT, Sakai H, Barbosa de Melo M, Lee MC,
467 Chan AS, Azhany Y, Dao TL, Ikeda Y, Perez-Grossmann RA, Zarnowski T, Day AC,
468 Jonas JB, Tam PO, Tran TA, Ayub H, Akhtar F, Micheal S, Chew PT, Aljasim LA, Dada
469 T, Luu TT, Awadalla MS, Kitnarong N, Wanichwecharungruang B, Aung YY, Mohamed-
470 Noor J, Vijayan S, Sarangapani S, Husain R, Jap A, Baskaran M, Goh D, Su DH, Wang
471 H, Yong VK, Yip LW, Trinh TB, Makornwattana M, Nguyen TT, Leuenberger EU, Park
472 KH, Wiyogo WA, Kumar RS, Tello C, Kurimoto Y, Thapa SS, Pathanapitoon K, Salmon
473 JF, Sohn YH, Fea A, Ozaki M, Lai JS, Tantisevi V, Khaing CC, Mizoguchi T, Nakano S,
474 Kim CY, Tang G, Fan S, Wu R, Meng H, Nguyen TT, Tran TD, Ueno M, Martinez JM,
475 Ramli N, Aung YM, Reyes RD, Vernon SA, Fang SK, Xie Z, Chen XY, Foo JN, Sim KS,
476 Wong TT, Quek DT, Venkatesh R, Kavitha S, Krishnadas SR, Soumittra N, Shantha B,
477 Lim BA, Ogle J, de Vasconcellos JP, Costa VP, Abe RY, de Souza BB, Sng CC, Aquino
478 MC, Kosior-Jarecka E, Fong GB, Tamanaja VC, Fujita R, Jiang Y, Waseem N, Low S,
479 Pham HN, Al-Shahwan S, Craven ER, Khan MI, Dada R, Mohanty K, Faiq MA, Hewitt
480 AW, Burdon KP, Gan EH, Prutthipongsit A, Patthanathamrongkasem T, Catacutan MA,
481 Felarca IR, Liao CS, Rusmayani E, Istiantoro VW, Consolandi G, Pignata G, Lavia C,
482 Rojanapongpun P, Mangkornkanokpong L, Chansangpetch S, Chan JC, Choy BN,

- 483 Shum JW, Than HM, Oo KT, Han AT, Yong VH, Ng XY, Goh SR, Chong YF, Hibberd
484 ML, Seielstad M, Png E, Dunstan SJ, Chau NV, Bei J, Zeng YX, Karkey A, Basnyat B,
485 Pasutto F, Paoli D, Frezzotti P, Wang JJ, Mitchell P, Fingert JH, Allingham RR, Hauser
486 MA, Lim ST, Chew SH, Ebstein RP, Sakuntabhai A, Park KH, Ahn J, Boland G, Snippe
487 H, Stead R, Quino R, Zaw SN, Lukasik U, Shetty R, Zahari M, Bae HW, Oo NL, Kubota
488 T, Manassakorn A, Ho WL, Dallorto L, Hwang YH, Kiire CA, Kuroda M, Djamal ZE,
489 Peregrino JI, Ghosh A, Jeoung JW, Hoan TS, Srisamran N, Sandragasu T, Set SH,
490 Doan VH, Bhattacharya SS, Ho CL, Tan DT, Sihota R, Loon SC, Mori K, Kinoshita S,
491 Hollander AI, Qamar R, Wang YX, Teo YY, Tai ES, Hartleben-Matkin C, Lozano-Giral D,
492 Saw SM, Cheng CY, Zenteno JC, Pang CP, Bui HT, Hee O, Craig JE, Edward DP,
493 Yonahara M, Neto JM, Guevara-Fujita ML, Xu L, Ritch R, Liza-Sharmini AT, Wong TY,
494 Al-Obeidan S, Do NH, Sundaresan P, Tham CC, Foster PJ, Vijaya L, Tashiro K, Vithana
495 EN, Wang N, Aung T. Genome-wide association study identifies five new susceptibility
496 loci for primary angle closure glaucoma. *Nat Genet* 2016; 48: 556-562.
- 497 31. Beardsley J, Hoang NLT, Kibengo FM, Tung NLN, Binh TQ, Hung LQ, Chierakul W,
498 Thwaites GE, Chau NVV, Nguyen TTT, Geskus RB, Day JN. Do Intracerebral Cytokine
499 Responses Explain the Harmful Effects of Dexamethasone in Human Immunodeficiency
500 Virus-associated Cryptococcal Meningitis? *Clin Infect Dis* 2019; 68: 1494-1501.
- 501 32. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de
502 Bakker PI, Daly MJ, Sham PC. PLINK: a tool set for whole-genome association and
503 population-based linkage analyses. *Am J Hum Genet* 2007; 81: 559-575.
- 504 33. Heemskerk AD, Bang ND, Mai NT, Chau TT, Phu NH, Loc PP, Chau NV, Hien TT, Dung
505 NH, Lan NT, Lan NH, Lan NN, Phong le T, Vien NN, Hien NQ, Yen NT, Ha DT, Day JN,
506 Caws M, Merson L, Think TT, Wolbers M, Thwaites GE, Farrar JJ. Intensified
507 Antituberculosis Therapy in Adults with Tuberculous Meningitis. *N Engl J Med* 2016;
508 374: 124-134.

- 509 34. Thwaites GE, Nguyen DB, Nguyen HD, Hoang TQ, Do TT, Nguyen TC, Nguyen QH,
510 Nguyen TT, Nguyen NH, Nguyen TN, Nguyen NL, Nguyen HD, Vu NT, Cao HH, Tran
511 TH, Pham PM, Nguyen TD, Stepniowska K, White NJ, Tran TH, Farrar JJ.
512 Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. *N*
513 *Engl J Med* 2004; 351: 1741-1751.
- 514 35. van Laarhoven A, Dian S, Ruesen C, Hayati E, Damen M, Annisa J, Chaidir L, Ruslami R,
515 Achmad TH, Netea MG, Alisjahbana B, Rizal Ganiem A, van Crevel R. Clinical
516 Parameters, Routine Inflammatory Markers, and LTA4H Genotype as Predictors of
517 Mortality Among 608 Patients With Tuberculous Meningitis in Indonesia. *J Infect Dis*
518 2017; 215: 1029-1039.
- 519 36. van Laarhoven A, Dian S, Aguirre-Gamboa R, Avila-Pacheco J, Ricano-Ponce I, Ruesen C,
520 Annisa J, Koeken V, Chaidir L, Li Y, Achmad TH, Joosten LAB, Notebaart RA, Ruslami
521 R, Netea MG, Verbeek MM, Alisjahbana B, Kumar V, Clish CB, Ganiem AR, van Crevel
522 R. Cerebral tryptophan metabolism and outcome of tuberculous meningitis: an
523 observational cohort study. *Lancet Infect Dis* 2018; 18: 526-535.
- 524 37. Poral TG. Analysis Methods. 08/20/2019 07/30/2021]. Available from:
525 <https://www.gtexportal.org/home/documentationPage#staticTextAnalysisMethods>.
- 526 38. Buniello A, MacArthur JAL, Cerezo M, Harris LW, Hayhurst J, Malangone C, McMahon A,
527 Morales J, Mountjoy E, Sollis E, Suveges D, Vrousitou O, Whetzel PL, Amodè R, Guillen
528 JA, Riat HS, Trevanion SJ, Hall P, Junkins H, Flicek P, Burdett T, Hindorf LA,
529 Cunningham F, Parkinson H. The NHGRI-EBI GWAS Catalog of published genome-
530 wide association studies, targeted arrays and summary statistics 2019. *Nucleic Acids*
531 *Res* 2019; 47: D1005-D1012.
- 532 39. Shelton JF, Shastri AJ, Ye C, Weldon CH, Filshtein-Sonmez T, Coker D, Symons A,
533 Esparza-Gordillo J, and Me C-T, Aslibekyan S, Auton A. Trans-ancestry analysis reveals

- 534 genetic and nongenetic associations with COVID-19 susceptibility and severity. *Nat*
535 *Genet* 2021; 53: 801-808.
- 536 40. Han Y, Jia Q, Jahani PS, Hurrell BP, Pan C, Huang P, Gukasyan J, Woodward NC, Eskin E,
537 Gilliland FD, Akbari O, Hartiala JA, Allayee H. Genome-wide analysis highlights
538 contribution of immune system pathways to the genetic architecture of asthma. *Nat*
539 *Commun* 2020; 11: 1776.
- 540 41. Koeppen M, McNamee EN, Brodsky KS, Aherne CM, Faigle M, Downey GP, Colgan SP,
541 Evans CM, Schwartz DA, Eltzschig HK. Detrimental role of the airway mucin Muc5ac
542 during ventilator-induced lung injury. *Mucosal Immunol* 2013; 6: 762-775.
- 543 42. MUC5AC. The Human Protein Atlas. [https://www.proteinatlas.org/ENSG00000215182-](https://www.proteinatlas.org/ENSG00000215182-MUC5AC)
544 [MUC5AC](https://www.proteinatlas.org/ENSG00000215182-MUC5AC); Accessed 12-13-2021.
- 545 43. Davis A, Meintjes G, Wilkinson RJ. Treatment of Tuberculous Meningitis and Its
546 Complications in Adults. *Curr Treat Options Neurol* 2018; 20: 5.
- 547 44. Vuckovic D, Bao EL, Akbari P, Lareau CA, Mousas A, Jiang T, Chen MH, Raffield LM,
548 Tardaguila M, Huffman JE, Ritchie SC, Megy K, Ponstingl H, Penkett CJ, Albers PK,
549 Wigdor EM, Sakaue S, Moscati A, Manansala R, Lo KS, Qian H, Akiyama M, Bartz TM,
550 Ben-Shlomo Y, Beswick A, Bork-Jensen J, Bottinger EP, Brody JA, van Rooij FJA,
551 Chitrala KN, Wilson PWF, Choquet H, Danesh J, Di Angelantonio E, Dimou N, Ding J,
552 Elliott P, Esko T, Evans MK, Felix SB, Floyd JS, Broer L, Grarup N, Guo MH, Guo Q,
553 Greinacher A, Haessler J, Hansen T, Howson JMM, Huang W, Jorgenson E, Kacprowski
554 T, Kahonen M, Kamatani Y, Kanai M, Karthikeyan S, Koskeridis F, Lange LA, Lehtimaki
555 T, Linneberg A, Liu Y, Lyytikainen LP, Manichaikul A, Matsuda K, Mohlke KL, Mononen
556 N, Murakami Y, Nadkarni GN, Nikus K, Pankratz N, Pedersen O, Preuss M, Psaty BM,
557 Raitakari OT, Rich SS, Rodriguez BAT, Rosen JD, Rotter JI, Schubert P, Spracklen CN,
558 Surendran P, Tang H, Tardif JC, Ghanbari M, Volker U, Volzke H, Watkins NA, Weiss S,
559 Program VAMV, Cai N, Kundu K, Watt SB, Walter K, Zonderman AB, Cho K, Li Y, Loos

- 560 RJF, Knight JC, Georges M, Stegle O, Evangelou E, Okada Y, Roberts DJ, Inouye M,
561 Johnson AD, Auer PL, Astle WJ, Reiner AP, Butterworth AS, Ouwehand WH, Lettre G,
562 Sankaran VG, Soranzo N. The Polygenic and Monogenic Basis of Blood Traits and
563 Diseases. *Cell* 2020; 182: 1214-1231 e1211.
- 564 45. Cohen SB, Gern BH, Delahaye JL, Adams KN, Plumlee CR, Winkler JK, Sherman DR,
565 Gerner MY, Urdahl KB. Alveolar Macrophages Provide an Early Mycobacterium
566 tuberculosis Niche and Initiate Dissemination. *Cell Host Microbe* 2018; 24: 439-446
567 e434.
- 568 46. Griffiths KL, Ahmed M, Das S, Gopal R, Horne W, Connell TD, Moynihan KD, Kolls JK,
569 Irvine DJ, Artyomov MN, Rangel-Moreno J, Khader SA. Targeting dendritic cells to
570 accelerate T-cell activation overcomes a bottleneck in tuberculosis vaccine efficacy. *Nat*
571 *Commun* 2016; 7: 13894.
- 572 47. Dumas A, Corral D, Colom A, Levillain F, Peixoto A, Hudrisier D, Poquet Y, Neyrolles O.
573 The Host Microbiota Contributes to Early Protection Against Lung Colonization by
574 Mycobacterium tuberculosis. *Front Immunol* 2018; 9: 2656.
- 575 48. Fava VM, Schurr E. Evaluating the Impact of LTA4H Genotype and Immune Status on
576 Survival From Tuberculous Meningitis. *J Infect Dis* 2017; 215: 1011-1013.
577
578

Table 1: Association of *MUC5AC* SNP rs28737416 with diagnosis of TB meningitis and pulmonary TB

Genotype	<u>TB Meningitis</u>		OR (95% CI)	P-value
	Controls [†] (N = 1,139)	Cases (N = 407)		
C/C	582 (51.3%)	182 (45.4%)	1.24 (1.03, 1.49)	0.021
T/C	464 (40.9%)	169 (42.1%)		
T/T	89 (7.8%)	50 (12.5%)		
Genotype	<u>Pulmonary TB[‡]</u>		OR (95% CI)	P-value
	Controls [†] (N = 1,270)	Cases (N = 1,380)		
C/C	655 (51.6%)	662 (48.0%)	1.11 (0.98, 1.25)	0.100
T/C	510 (40.2%)	588 (42.6%)		
T/T	100 (7.9%)	129 (9.3%)		

The association between diagnosis of TB meningitis or pulmonary TB (analyzed separately) and *MUC5AC* SNP rs28737416 was compared between cases and controls as described in the methods. The total number of individuals with major homozygous (C/C), heterozygous (T/C) and minor homozygous (T/T) genotypes are shown.

* Genotype data were missing for 5 cases and 1 control.

† Controls were generated from the same cohort of participants with primary angle closure glaucoma.

Abbreviations: TB, tuberculosis; SNPs, single nucleotide polymorphisms; OR, odds ratio; CI, confidence interval.

Table 2: Baseline characteristics

General characteristics	Discovery Cohort N=211	Vietnam validation cohort N=87	Indonesia validation cohort (N=468)
Age	43 (28, 57)	41 (25, 57)*	28 (22-37)†
Male sex	131 (62.1%)	37 (46.8%)*	230 (55%)
Weight (kilograms)	49 (45, 55)	45 (40, 49)	N/A‡
Disease Characteristics			
Duration of illness prior to presentation (days)	14 (10, 30)	17 (12, 30)*	N/A‡
CSF WBC count (leukocytes/mm ³)	81 (28, 231) [§]	209 (82, 375)	155 (53-336)
Glasgow coma score	15 (13, 15)	14 (13, 15)	13 (12-15)†
HIV seropositive	0 (0%)	0 (0%)	50 (10.7%)
Diagnostic category			
Definite TBM	77 (36.5%)	51 (58.6%)	272 (65.1%)
Probable TBM	66 (31.3%)	27 (31.0%)	146 (34.9%)
Possible TBM	68 (32.2%)	9 (10.3%)	-

Results are presented as median (interquartile range) for continuous variables or number (%) for categorical variables.

Abbreviations: CSF, cerebral spinal fluid; WBC, white blood cell count; TBM, tuberculosis meningitis.

* N=79 due to missingness.

† N=412 due to missingness.

‡ Data not available.

§ N=204 due to missingness.

|| Participant diagnostic category at study end. Diagnostic categories were defined according to consensus criteria or study-specific criteria as described in the supplementary methods. Possible TBM was not defined in the Indonesia cohort.

Figure 1: Chromosome map and linkage disequilibrium plots of haplotype-tagging SNPs identified in *MUC5B* and *MUC5AC* gene regions.

A. *MUC5B* and *MUC5AC* genes and SNPs of interest are located on band 1 of the p arm of chromosome 11 as shown. Vertical lines represent sub-band intervals of 0.004. **B.** Linkage disequilibrium plots showing R^2 (left) and D' (right) values for tagging SNPs. The degree of shading is proportionate to the R^2 and D' values for paired SNPs. **C.** Table listing the minor allele frequency (MAF) for each SNP.

Figure 2: Evaluation of CSF cytokine expression in TBM patients with *MUC5B* and *MUC5AC* SNPs assessed by allelic, additive, and dominant genetic models.

(A) \log_2 TNF concentrations (pg/mL) measured in CSF were compared using Wilcoxon rank sum for tagging SNPs based on an allelic model (e.g., comparison of total number of alleles). For each SNP, the major allele is represented by black circles, and the minor allele is indicated by grey circles. Measured cytokine concentrations were counted twice, as all participants contribute two alleles. The association between *MUC5AC* SNP rs28737416 and additional \log_2 CSF cytokine concentrations (pg/mL) were evaluated using additive **(B)** and dominant genetic models **(C)**. For the additive model, cytokine concentrations were compared between those with the T/T (grey circles), T/C (open circles), or C/C (black circles) genotypes using the Kruskal-Wallis test. In the dominant model, the composite of the T/T and T/C genotypes (grey circles) were compared to the C/C genotype (black circles) using Wilcoxon rank-sum testing. For all graphs, the median is indicated by a thick, horizontal red line, and the interquartile range is represented by thin, horizontal red lines. To adjust for multiple comparisons, a Bonferroni correction was

applied to the results in B and C, and significance threshold adjusted to the level of $p < 0.005$. P-values for cytokines with statistically significant differences in expression after Bonferroni correction are shown.

Figure 3: Kaplan Meier curves comparing survival in a dominant allelic model of *MUC5AC* SNP rs28737416 in the discovery cohort.


Kaplan-Meier curves displaying time to death using a dominant allelic model comparing participants with the T/T and T/C genotypes to those with the C/C genotype are shown. Displayed p-values represent comparison of the survival distributions by the log-rank test.

Figure 4: Kaplan Meier curves comparing survival in a dominant allelic model of *MUC5AC* SNP rs28737416 in the validation cohorts.



Kaplan-Meier curves displaying time to death using a dominant allelic model comparing participants with T/T and T/C genotypes to those with the C/C genotype in the Vietnam validation cohort (**A**) and the Indonesia validation cohort (**B**) are shown. Displayed p-values represent comparison of the survival distributions by the log-rank test.

Figure 1

A.



B.



C.

SNP	MAF
rs28737416	0.34
rs2037089	0.03
rs7946008	0.03
rs6578810	0.40

Figure 2





Figure 3




No at risk

T/T and T/C genotype	119	104	98	88	87	86	84
C/C genotype	89	83	82	77	76	76	76

Figure 4


A.



No at risk

T/T and T/C genotypes	47	46	42	41	40	39	38
C/C genotype	40	39	39	39	39	39	39

B.



No at risk

T/T and T/C genotypes	287	175	164	149	133	128	121
C/C genotype	181	128	112	109	105	87	87